Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 7 of 7 results for degarelix

  1. Degarelix for treating advanced hormone-dependent prostate cancer (TA404)

    Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.

    Technology appraisal guidance
    Published
    24 August 2016
    View recommendations

    Sections for TA404

  2. Relugolix for treating hormone-sensitive prostate cancer [ID6187]

    In development [GID-TA11141] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Further research is recommended to resolve uncertainties about the clinical effectiveness of degarelix compared with luteinising hormone-releasing hormone (LHRH) agonists such as leuprorelin, goserelin and triptorelin for treating advanced hormone-dependent prostate cancer, particularly in subgroups of people with preexisting cardiovascular disease, people with skeletal (including spinal) metastases and people with impending ureteric and urethral obstruction. Research should be planned as part of well-conducted randomised clinical trials.

    recommended to resolve uncertainties about the clinical effectiveness of degarelix compared with luteinising hormone-releasing hormone...

    Research recommendation
    Published
    17 October 2016

  4. Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer TS ID 11933

    Awaiting development [GID-TA11443] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Past appeals and decisions

    March 2012 TA352 Prostate cancer (advanced, hormone dependent) - degarelix depot [ID590] 12 November 2014 TA832...

  6. Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]

    Discontinued [GID-TA10377]

    Technology appraisal guidance
    Discontinued

  7. Research recommendations

    recommended to resolve uncertainties about the clinical effectiveness of degarelix compared with luteinising hormone-releasing hormone...